Verrica Pharmaceuticals Inc’s filing revealed that its 10% Owner PERCEPTIVE ADVISORS LLC acquired Company’s shares for reported $0.84 million on Dec 29 ’23. In the deal valued at $7.24 per share,115,774 shares were bought. As a result of this transaction, PERCEPTIVE ADVISORS LLC now holds 7,099,182 shares worth roughly $54.31 million.
Then, PERCEPTIVE ADVISORS LLC bought 126,116 shares, generating $892,901 in total proceeds. Upon buying the shares at $7.08, the 10% Owner now owns 6,983,408 shares.
Before that, PERCEPTIVE ADVISORS LLC bought 79,726 shares. Verrica Pharmaceuticals Inc shares valued at $574,027 were divested by the 10% Owner at a price of $7.20 per share. As a result of the transaction, PERCEPTIVE ADVISORS LLC now holds 6,857,292 shares, worth roughly $52.46 million.
Needham upgraded its Verrica Pharmaceuticals Inc [VRCA] rating to a Buy from a a Hold in a research note published recently. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in late March with a ‘”a Buy”‘ rating. RBC Capital Mkts also remained covering VRCA and has increased its forecast on February 13, 2023 with a “an Outperform” recommendation from previously “Sector perform” rating. RBC Capital Mkts revised its rating on May 25, 2022. It rated VRCA as “a Sector perform” which previously was an “an Outperform”.
Price Performance Review of VRCA
On Tuesday, Verrica Pharmaceuticals Inc [NASDAQ:VRCA] saw its stock jump 4.65% to $7.65. Over the last five days, the stock has gained 9.83%. Verrica Pharmaceuticals Inc shares have risen nearly 4.51% since the year began. Nevertheless, the stocks have risen 16.79% over the past one year. While a 52-week high of $7.76 was reached on 05/07/24, a 52-week low of $2.86 was recorded on 03/20/24. SMA at 50 days reached $6.09, while 200 days put it at $5.03. A total of 0.35 million shares were traded, compared to the trading of 0.24 million shares in the previous session.
Levels Of Support And Resistance For VRCA Stock
The 24-hour chart illustrates a support level at 7.31, which if violated will result in even more drops to 6.97. On the upside, there is a resistance level at 7.89. A further resistance level may holdings at 8.13. The Relative Strength Index (RSI) on the 14-day chart is 69.81, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.42, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 11.20%. Stochastics %K at 77.36% indicates the stock is a holding.
The most recent change occurred on May 14, 2021 when RBC Capital Mkts began covering the stock and recommended ‘”an Outperform”‘ rating along with a $19 price target.
